Document is current

Article History

Received: 25 February 2019

Accepted: 1 March 2019

First Online: 9 March 2019

Compliance with ethical standards

:

: F.L. reports personal fees from AstraZeneca, Celgene, Jounce; research grants to institution from Bristol-Myers Squibb, Calithera, Chugai, Genentech/Roche, Immunomedics, Inivata, Pfizer, Regeneron, Tesaro. C.D. reports personal fees from Amgen, Pfizer, Puma Biotechnology, Roche/Genentech; research grants from Amgen, Pfizer, Puma Biotechnology, Roche/Genentech. A.B. reports honoraria from Bristol-Myers Squibb. A.F.U. reports personal fees from Glenmark Pharmaceuticals. KLS reports ownership interest in AbbVie, Abbott Laboratories; honoraria from ASiM CME; research grants to self from Pfizer/NCCN and to institution from AstraZeneca, Pfizer, Galena BioPharma, Novartis, Pfizer, Syndax. P.R.P. reports ownership interest in Immunonet BioSciences; personal fees from Genentech/Roche, Heron Therapeutics, Immunonet BioSciences, OncoPlex Diagnostics, Personalized Cancer Therapy, Pfizer, Puma Biotechnology; research grants to institution from Advanced Cancer Therapeutics, Caris Centers of Excellence, Cascadian Therapeutics, Fabre-Kramer, Genentech/Roche, Pfizer, Pieris Pharmaceuticals; and payments for patents, royalties, or other intellectual property for U.S. Patent Nos. 8,486,413; 8,501,417; 9,023,362; and 294 9,745,377. R.N. reports personal fees from Bristol-Myers Squibb; travel and accommodation from Bristol-Myers Squibb, Caris Life Sciences. P.H. reports employment by AstraZeneca; C.I. reports honoraria from AstraZeneca, Genentech, Roche; personal fees from AstraZeneca, Genentech, NanoString Technologies, Novartis, Pfizer, Puma Biotechnology, Syndax; speakers’ bureau payments from AstraZeneca, Genentech, Pfizer; research grants to institution from Genentech, Novartis, Pfizer, Tesaro; and payments for patents, royalties, or other intellectual property from UpToDate, McGraw Hill. S.M.S. reports honoraria from Novartis, personal fees from Cardinal Health, Daiichi-Sankyo, Eli Lilly & Co., Genentech/Roche, Genomic Health, Inivata, Peiris Pharmaceuticals, Tocagen; research grants to institution from Genentech; travel and accommodation from Caris Centers of Excellence, Daiichi-Sankyo, Eli Lilly & Co., Genentech/Roche, NanoString Technologies; payments for participation on OlympiA IDMC from AstraZeneca. All remaining authors have declared no conflicts of interest.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.